Remacemide (FPL 12924) is an orally active, non-competitive, low-affinity NMDA receptor antagonist. Remacemide shows neuroprotection activity in animal models of poxia and ischemic stroke. Remacemide is also an anticonvulsant, and can be used in Parkinson's disease and Huntington's disease research.
References:
[1]. Schachter SC, et al. Remacemide: current status and clinical applications. Expert Opin Investig Drugs. 2000 Apr;9(4):871-83.
[2]. Dyker AG, et al. Remacemide drochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke. Stroke. 1999 Sep;30(9):1796-801.
[3]. Greenamyre JT, et al. Antiparkinsonian effects of remacemide drochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol. 1994 Jun;35(6):655-61.
[4]. Kieburtz K, et al. A controlled trial of remacemide drochloride in Huntington's disease. Mov Disord. 1996 May;11(3):273-7.